Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H21N6O7S2.H |
| Molecular Weight | 546.576 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C([O-])=O)\C4=CSC(N)=N4)C([O-])=O
InChI
InChIKey=ORFOPKXBNMVMKC-DWVKKRMSSA-N
InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4268 |
|||
Target ID: CHEMBL1813 |
|||
Target ID: CHEMBL1814 |
|||
Target ID: CHEMBL4269 |
|||
Target ID: CHEMBL2549 |
|||
Target ID: CHEMBL5539 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FORTAZ Approved UseCeftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1985 |
|||
| Curative | FORTAZ Approved UseCeftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1985 |
|||
| Curative | FORTAZ Approved UseCeftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1985 |
|||
| Primary | FORTAZ Approved UseCeftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1985 |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
21.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088186 |
75 mg/kg other, intravenous dose: 75 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
CEFTAZIDIME serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088186 |
75 mg/kg 1 times / day other, intravenous dose: 75 mg/kg route of administration: Intravenous experiment type: OTHER co-administered: |
CEFTAZIDIME unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
285 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088186 |
25 mg/kg 3 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CEFTAZIDIME serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2088186 |
25 mg/kg 3 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CEFTAZIDIME serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 g 3 times / day multiple, intravenous Highest studied dose Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Condition: pneumonia Age Group: adult Sex: unknown Population Size: 1 Sources: |
|
300 mg/kg 14 times / day multiple, intravenous Highest studied dose Dose: 300 mg/kg, 14 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 14 times / day Sources: |
unhealthy, children n = 15 Health Status: unhealthy Condition: cystic fibrosis Age Group: children Sex: unknown Population Size: 15 Sources: |
Other AEs: Urticaria, Itchy rash... Other AEs: Urticaria (3 patients) Sources: Itchy rash (4 patients) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Urticaria | 3 patients | 300 mg/kg 14 times / day multiple, intravenous Highest studied dose Dose: 300 mg/kg, 14 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 14 times / day Sources: |
unhealthy, children n = 15 Health Status: unhealthy Condition: cystic fibrosis Age Group: children Sex: unknown Population Size: 15 Sources: |
| Itchy rash | 4 patients | 300 mg/kg 14 times / day multiple, intravenous Highest studied dose Dose: 300 mg/kg, 14 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 14 times / day Sources: |
unhealthy, children n = 15 Health Status: unhealthy Condition: cystic fibrosis Age Group: children Sex: unknown Population Size: 15 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| inconclusive | ||||
| no | ||||
| no | ||||
| no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. | 1993 Mar |
|
| [Analysis of the etiologic structure of urinary tract infection and antibiotic-resistance of its pathogens]. | 1997 |
|
| Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. | 2001 Aug |
|
| Acute renal failure and cystic fibrosis. | 2003 Jul |
Patents
Sample Use Guides
The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient.
Route of Administration:
Other
Ceftazidime–avibactam and comparator antibacterial agents were tested by reference broth microdilution against 417non-repetitive Gram-negative bacilli (387 unselected, plus 30selected blaKPC-positive, meropenem – nonsusceptible, Kleb-siella pneumoniae) collected prospectively from medical centersat Hospital das Clínicas da Faculdade de Medicina da Uni-versidade de São Paulo, Brazil, in 2014 and 2015. Minimum inhibitory concentrations (MICs), one per isolate, were determined by reference Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods using frozen microtiter plates pre-loaded with antibiotic-containing growth medium. MICs ofceftazidime–avibactam were measured by varying the concen-tration of ceftazidime in twofold increments with avibactamat a fixed concentration of 4 mg/L. Addition of avibactam at 4 mg/L decreased MICs of cef-tazidime against unselected Enterobacteriaceae, especially K.pneumoniae, Citrobacter freundii, and Enterobacter cloacae, among which MIC90values decreased from 128 to >128 mg/L to0.5–4 mg/L. Among the unselected isolates of these three species 37–73% were susceptible to ceftazidime, whereas 100%were susceptible to ceftazidime–avibactam.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
WHO-ATC |
J01DD02
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000175488
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
LIVERTOX |
NBK548666
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
LIVERTOX |
NBK547862
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3508
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
4886
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
759260
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
DZR1ENT301
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
5481173
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
72558-82-8
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
DZR1ENT301
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
100000092630
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
SUB07422MIG
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
m3218
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
1545984
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
276-715-9
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
C90827
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
SUB115175
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5022770
Created by
admin on Fri Dec 15 15:53:49 GMT 2023 , Edited by admin on Fri Dec 15 15:53:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
